A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma
NCT05461209
Age 18 +
Sex Both
Phase Phase 3
Third Opinion Trial Synopsis
This study is trying to see which medicine is better at helping people with cancer. They want to compare talquetamab to belantamab mafodotin and see which one helps people more in terms of either getting better or not getting worse.
This study is trying to see which medicine is better at helping people with cancer. They want to compare talquetamab to belantamab mafodotin and see which one helps people more in terms of either getting better or not getting worse.
Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to compare the efficacy of talquetamab versus belantamab mafodotin in terms of overall response rate (ORR) or progression-free survival (PFS).
The purpose of this study is to compare the efficacy of talquetamab versus belantamab mafodotin in terms of overall response rate (ORR) or progression-free survival (PFS).
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
